Approval · Notice of Compliance 37684 · 2026
SARCLISA: Notice of Compliance 37684
Issued June 10, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37684
- Date
- June 10, 2026
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: Sarclisa (isatuximab for injection) is indicated in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SARCLISA | Not yet assigned | — |
Medicinal ingredients
- ISATUXIMAB 100 MG per VIAL
- ISATUXIMAB 500 MG per VIAL